Respana Therapeutics, Inc
Philadelphia, PA · Biotech · Private
RT-002, a monoclonal antibody targeting SP-R210 receptor for treating inflammatory complications in acute respiratory conditions
- Grants
- $4.7M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Novel therapeutic monoclonal antibody targeting SP-R210 isoforms to prevent influenza disease progression and expedite resolution of comorbidities | $298,498 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel therapeutic monoclonal antibody targeting SP-R210 isoforms to prevent influenza disease progression and expedite resolution of comorbidities | $298,498 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Treatment of Inflammatory Complications of Viral Pneumonia | $300,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Treatment of Inflammatory Complications of Viral Pneumonia | $300,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Treatment of Inflammatory Complications of Respiratory Infection | $1,000,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Treatment of Inflammatory Complications of Respiratory Infection | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Treatment of Inflammatory Complications of Respiratory Infection | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Treatment of Inflammatory Complications of Respiratory Infection | $463,597 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1646 | IMMUNARTES LLC | — | — |
| 1647 | GENERAL NUTRACEUTICAL TECHNOLOGY LLC | — | — |
| 1648 | Boston Immune Technologies And Therapeutics Inc. | — | — |
| 1649 | Respana Therapeutics, Inc | — | — |
| 1650 | Seawolf Therapeutics | — | — |
| 1651 | KARIS BIO USA, INC. | — | — |
| 1652 | Eureka Therapeutics, Inc. | — | $86M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.